Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
US-2024352036-A1 · Oct 24, 2024 · US
US9458194B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9458194-B2 |
| Application number | US-201414783689-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 15, 2014 |
| Priority date | Apr 15, 2013 |
| Publication date | Oct 4, 2016 |
| Grant date | Oct 4, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Compounds of general formula (I): their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, cosmetic and/or pharmaceutical compositions which contain them and their use in medicine, and in the treatment and/or care of the skin, particularly in the aging and photoaging of the skin, and more particularly for the treatment and/or prevention of wrinkles and/or stretch marks.
Opening claim text (preview).
The invention claimed is: 1. A compound of general formula (I): its stereoisomers, mixtures thereof and/or its cosmetic or pharmaceutical acceptable salts, wherein: AA 1 is selected from the group consisting of -Asp-, -Glu-, -Asn-, -Gln-, -Lys- and -Gly-; AA 2 is selected from the group consisting of -Val-, -Leu-, -Ile-, -Met-, -Cit-, -His-, -Thr- and -Gln -; AA 3 is selected from the group consisting of -Tyr-, -Trp- and 4-Aminobenzoyl (-4-Abz); n is selected from 1, 2, 3 and 4; R 3 is selected from the group consisting of H and -AA 2 -AA 1 -R 1 ; R 1 is selected from the group consisting of H, a polymer derived from polyethylene glycol, substituted or unsubstituted non-cyclic aliphatic groups, substituted or unsubstituted alicyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl and R 6 —CO—, wherein R 6 is selected from the group consisting of H, substituted or unsubstituted non-cyclic aliphatic groups, substituted or unsubstituted alicyclyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted heterocyclyl and substituted or unsubstituted heteroarylalkyl; R 2 is selected from the group consisting of —NR 4 R 5 , —OR 4 and —SR 4 , wherein R 4 and R 5 are independently selected from the group consisting of H, a polymer derived from polyethylene glycol, substituted or unsubstituted non-cyclic aliphatic groups, substituted or unsubstituted alicyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted aralkyl; and R 1 and R 2 are not α-amino acids, with the condition that if R 3 is H, then AA 2 is selected from the group consisting of -Val-, -Leu-, -Ile- and -Met-, and AA 1 is selected from the group consisting of -Asp-, -Glu-, -Asn- and -Gln-. 2. The compound according to claim 1 , wherein AA 1 is selected from the group consisting of -Asp-, -Glu-, -Asn- and -Gln-, AA 2 is selected from the group consisting of -Val-, -Leu-, -Ile- and -Met-, R 3 is H, and AA 3 is -Tyr- or -Trp-. 3. The compound according to claim 1 , wherein AA 1 is selected from the group consisting of -Lys-, -Gly- and -Asn-, AA 2 is selected from the group consisting of -His-, -Thr-, -Gln-, and -Cit- and AA 3 is 4-Abz. 4. The compound according to claim 1 wherein R 1 is selected from the group consisting of H, acetyl, lauroyl, myristoyl and palmitoyl, AA 1 is -L-Asp-, AA 2 is -L-Val- and AA 3 is -L-Tyr-, R 3 is H, n is 4 and R 2 is selected from the group consisting of —NR 4 R 5 and —OR 4 wherein R 4 and R 5 are independently selected from H, methyl, ethyl, hexyl, dodecyl and hexadecyl. 5. A cosmetic or pharmaceutical composition which comprises at least one compound of general formula (I), its stereoisomers, mixtures thereof and/or its cosmetically or pharmaceutically acceptable salts, according to claim 1 , together with at least one cosmetically or pharmaceutically acceptable excipient or adjuvant. 6. The composition according to claim 5 , wherein said compound of general formula (I), its stereoisomers, mixtures thereof and/or its cosmetically or pharmaceutically acceptable salts, is incorporated into a cosmetic or pharmaceutically acceptable delivery system or sustained release system selected from the group consisting of liposomes, mixed liposomes, oleosomes, niosomes, ethosomes, milliparticles, microparticles, nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, sponges, cyclodextrins, vesicles, micelles, mixed micelles of surfactants, surfactant-phospholipid mixed micelles, millispheres, microspheres, nanospheres, lipospheres, millicapsules, microcapsules, nanocapsules, microemulsions and nanoemulsions or is absorbed onto an organic solid polymer or solid mineral support selected from the group consisting of talc, bentonite, silica, starch and maltodextrin. 7. The composition according to claim 5 , wherein said composition is in a formulation selected from the group consisting of creams, multiple emulsions, anhydrous compositions, aqueous dispersions, oils, milks, balsams, foams, lotions, gels, cream gels, hydroalcoholic solutions, hydroglycolic solutions, hydrogels, liniments, sera, soaps, shampoos, conditioners, serums, polysaccharide films, ointments, mousses, pomades, powders, bars, pencils, sprays, aerosols, capsules, gelatin capsules, soft capsules, hard capsules, tablets, sugar coated tablets, tablets, pills, powders, granules, chewing gum, solutions, suspensions, emulsions, syrups, elixirs, jellies and gelatins. 8. The composition according to claim 5 , wherein said composition also comprises at least one cosmetically or pharmaceutically acceptable adjuvant selected from the group consisting of agents stimulating the synthesis of dermal or epidermal macromolecules and/or capable of inhibiting or preventing their degradation, collagen synthesis-stimulating agents, elastin synthesis-stimulating agents, decorin synthesis-stimulating agents, lamin in synthesis-stimulating agents, defensin synthesis-stimulating agents, chaperone synthesis-stimulating agents, cAMP synthesis-stimulating agents, AQP-3 modulating agents, aquaporin synthesis-modulating agents, proteins from the aquaporin family, hyaluronic acid synthesis-stimulating agents, glycosaminoglycan synthesis-stimulating agents, fibronectin synthesis-stimulating agents, sirtuin synthesis-stimulating agents, agents activating sirtuins, heat shock proteins, heat shock protein synthesis-stimulating agents, agents stimulating the synthesis of lipids and components of the stratum corneum, ceramides, fatty acids, agents that inhibit collagen degradation, agents that inhibit matrix metalloproteases, agents that inhibit elastin degradation, agents that inhibit serine proteases, agents stimulating fibroblast proliferation, agents stimulating keratinocyte proliferation, agents stimulating adipocyte proliferation, agents stimulating melanocyte proliferation, agents stimulating keratinocyte differentiation, agents stimulating or delaying adipocyte differentiation, DNA protecting agents, DNA repair agents, stem cell protecting agents, agents for the treatment and/or care of sensitive skin, agents with firming and/or redensifying and/or restructuring activity, anti-stretch mark agents, agents inhibiting neuronal exocytosis, anticholinergic agents, agents inhibiting muscular contraction, anti-aging agents, anti-wrinkle agents, antiperspirant agents, anti-inflammatory agents and/or analgesics, anti-itching agents, calming agents, anesthetic agents, inhibitors of acetylcholine-receptor aggregation, agents inhibiting acetylcholinesterase, dermo-relaxant agents, melanin synthesis inhibiting or stimulating agents, whitening or depigmenting agents, propigmenting agents, self-tanning agents, NO-synthase inhibiting agents, 5α-reductase inhibiting agents, lysyl- and/or prolyl hydroxylase inhibiting agents, antioxidants, free radical scavengers and/or agents against atmospheric pollution, reactive carbonyl species scavengers, anti-glycation agents, detoxifying agents, antihistamine agents, antiviral agents, antiparasitic agents, emulsifiers, emollients, organic solvents, liquid propellants, skin conditioners, humectants, substances which retain moisture, alpha hydroxy acids, beta hydroxy acids, moisturizers, hydrolytic epidermal enzymes, vitamins, amino acids, proteins, pigments, colorants, dyes, biopolymers, gelling polymers, thickening agents, surfactants, softening ag
Drugs for disorders of the cardiovascular system · CPC title
Antineoplastic agents · CPC title
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Ophthalmic agents · CPC title
Tetrapeptides · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.